Abstract: The present disclosure relates to a truncated body of IL7R?. The amino acid sequence of the truncated body of IL7R? s a sequence shown in SEQ ID NO. 1. A T cell expressing a chimeric antigen receptor containing the truncated body of IL7R? can effectively kill a tumor cell.
Type:
Application
Filed:
July 30, 2021
Publication date:
February 15, 2024
Applicant:
Beijing Neurosurgical Institute
Inventors:
Wei ZHANG, Tao JIANG, You ZHAI, Guanzhang LI
Abstract: The disclosure relates to an anti-CD44 single-chain antibody and use thereof in preparing a drug for treating a tumor. The amino acid sequence of the anti-CD44 single-chain antibody includes a sequence shown in SEQ ID NO. 1. T lymphocytes expressing the anti-CD44 single-chain antibody provided in the present disclosure can specifically kill CD44-positive tumor cells and have high specificity as well as strong killing ability.
Type:
Application
Filed:
July 30, 2021
Publication date:
October 12, 2023
Applicant:
Beijing Neurosurgical Institute
Inventors:
Wei ZHANG, Tao JIANG, You ZHAI, Guanzhang LI
Abstract: The disclosure relates to an anti-CD133 single-chain antibody. The amino acid sequence of the anti-CD133 single-chain antibody comprises a sequence shown in SEQ ID NO. 1. T lymphocytes expressing the anti-CD133 single-chain antibody can specifically kill CD133-positive tumor cells and have higher specificity and stronger killing ability.
Type:
Application
Filed:
July 30, 2021
Publication date:
October 5, 2023
Applicant:
Beijing Neurosurgical Institute
Inventors:
Wei ZHANG, Tao JIANG, You ZHAI, Guanzhang LI
Abstract: The disclosure relates to an anti-TIM3 single-chain antibody. The amino acid sequence of the anti-TIM3 single-chain antibody is a sequence shown in SEQ ID NO. 1. T lymphocytes expressing the anti-TIM3 single-chain antibody can effectively kill tumor cells.
Type:
Application
Filed:
July 30, 2021
Publication date:
September 21, 2023
Applicant:
Beijing Neurosurgical Institute
Inventors:
Wei ZHANG, Tao JIANG, You ZHAI, Guanzhang LI
Abstract: Provided are cDNA, mRNA serving as a reverse transcription template of the cDNA, a protein coded by the mRNA, and a kit and system for evaluating a glioma prognosis. The sequence of the cDNA contains a fragment of SEQ ID NO: 1 or the sequence of the cDNA contains a complementary fragment of the fragment of SEQ ID NO: 1, wherein the fragment of SEQ ID NO: 1 at least contains the sequences of positions 2635-2652, 2623-2640 or 2627-2645 of SEQ ID NO: 1.
Type:
Application
Filed:
April 20, 2021
Publication date:
June 22, 2023
Applicant:
Beijing Neurosurgical Institute
Inventors:
Tao JIANG, Zheng ZHAO, Ruichao CHAI, Jing CHEN
Abstract: A kit for evaluating the sensitivity of a patient to an MET inhibitor is provided. The kit includes a first primer pair capable of specifically amplifying a first nucleotide sequence, and/or a first probe capable of being specifically bonded to the first nucleotide sequence, wherein the first nucleotide sequence is as shown in SEQ ID NO: 1, and/or the kit comprises a second primer pair capable of specifically amplifying a second nucleotide sequence, and/or a second probe capable of being specifically bonded to the second nucleotide sequence, wherein the second nucleotide sequence is as shown in SEQ ID NO: 4. The kit provided is capable of screening the patients sensitive to an MET inhibitor.
Abstract: Provided are a kit and system for evaluating glioma and/or gastric adenocarcinoma prognosis. The kit includes a first primer pair capable of specifically amplifying a cDNA fragment of SEQ ID NO: 1, and/or a first probe capable of specifically hybridizing to the cDNA fragment of SEQ ID NO: 1, wherein the cDNA fragment of SEQ ID NO: 1 at least contains a cDNA sequence at positions 4057-4074, positions 4067-4084 or positions 4064-4079 of SEQ ID NO: 1.
Type:
Application
Filed:
April 20, 2021
Publication date:
May 11, 2023
Applicant:
Beijing Neurosurgical Institute
Inventors:
Tao JIANG, Jing CHEN, Ruichao CHAI, Zheng ZHAO
Abstract: The present invention provides uses of a compound represented by formula A in the preparation of drugs for treating brain glioma and particularly glioblastoma. Particularly provided are uses of the compound represented by formula A in the preparation of drugs for treating expression of specific fusion protein. By means of the technical solution of the present invention, typing of brain glioblastoma can be implemented, a drug administration can be carried out for a specific patient group, and precise treatment can be implemented.
Type:
Grant
Filed:
December 21, 2016
Date of Patent:
August 2, 2022
Assignees:
BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY, BEIJING NEUROSURGICAL INSTITUTE
Abstract: The present invention provides an artificial synthetic cDNA (complementary deoxyribonucleic acid). The said artificial synthetic cDNA encodes a fused protein which is specifically presented in secondary glioblastoma, and the said artificial synthetic cDNA can be used as a biomarker for detecting the secondary glioblastoma. The present invention further provides a method for detecting secondary glioblastoma. According to the above technical solutions, the accuracy in distinguishing the secondary glioblastoma from primary glioblastoma is effectively improved in the present invention.
Type:
Grant
Filed:
July 15, 2015
Date of Patent:
December 11, 2018
Assignees:
Beijing Neurosurgical Institute, Beijing Institute for Brain Disorders